Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(n/a)
# 4,350
Out of 4,711 analysts
4
Total ratings
n/a
Success rate
-28.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Buy | $45 | $2.23 | +1,917.94% | 1 | Dec 5, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $17.59 | +64.87% | 1 | Dec 5, 2024 | |
| GANX Gain Therapeutics | Initiates: Buy | $7 | $1.56 | +348.72% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.65 | +506.06% | 1 | Dec 5, 2024 |
CervoMed
Dec 5, 2024
Initiates: Buy
Price Target: $45
Current: $2.23
Upside: +1,917.94%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $17.59
Upside: +64.87%
Gain Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $7
Current: $1.56
Upside: +348.72%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.65
Upside: +506.06%